TME Pharma NV

ALTME

Company Profile

  • Business description

    TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

  • Contact

    Max-Dohrn-Street 8-10
    Berlin10589
    DEU

    T: +49 30166370820

    https://www.tmepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

Here’s how to value a share

Our best resources to help investors determine the value of a share.
stocks

How to avoid dividend disaster

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks

GyG punished by market after solid earnings

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0045.00-0.48%
CAC 407,918.6351.06-0.64%
DAX 4024,317.0046.09-0.19%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,829.91725.302.89%
NASDAQ21,496.54396.221.88%
Nikkei 22542,807.82197.650.46%
NZX 50 Index13,079.50114.57-0.87%
S&P 5006,466.910.000.00%
S&P/ASX 2008,972.4052.00-0.58%
SSE Composite Index3,883.5657.801.51%

Market Movers